埼玉県立がんセンターは、埼玉県北足立郡伊奈町にある医療機関。埼玉県が運営する県立病院として設立され、2021年4月に「地方独立行政法人埼玉県立病院機構」による運営に移行した。埼玉県の都道府県がん診療連携拠点病院に指定されている。埼玉大学大学院理工学研究科の連携大学院でもある。

During the past decade, Saitama Cancer Center conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 10 clinical trials were completed, i.e. on average, 26.3% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 8 clinical trials were completed. i.e. 42.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saitama Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Daiichi Sankyo, Inc." with 4 trials sponsored, "Incyte Corporation" with 4 trials sponsored, "BeiGene" with 3 trials sponsored and "Daiichi Sankyo Co., Ltd." with 3 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saitama Cancer Center" #1 collaborator was "AstraZeneca" with 5 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator and "Alpha-A, Inc." with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Saitama Cancer Center" are "Breast Cancer" (4 trials), "Non-Small Cell Lung Cancer" (3 trials), "Epithelial Ovarian Cancer" (2 trials), "Head and Neck Cancer" (2 trials) and "Non-small Cell Lung Cancer (NSCLC)" (2 trials). Many other conditions were trialed in "Saitama Cancer Center" in a lesser frequency.

Most popular intervention types in "Saitama Cancer Center" are "Drug" (43 trials), "Other" (3 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (9 trials), "Cisplatin" (6 trials), "Placebo" (6 trials), "Carboplatin" (5 trials) and "Gemcitabine" (5 trials). Other intervention names were less common.

The vast majority of trials in "Saitama Cancer Center" are 39 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Saitama Cancer Center". undefined are not yet recruiting, 15 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in Saitama Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Saitama Cancer Center, 4 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".